Analysts Set Vera Therapeutics, Inc. (NASDAQ:VERA) Target Price at $32.29

Vera Therapeutics, Inc. (NASDAQ:VERA) has earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $32.29.

A number of equities research analysts have issued reports on the company. Oppenheimer started coverage on Vera Therapeutics in a research note on Thursday, January 25th. They issued an “outperform” rating and a $26.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Vera Therapeutics in a research report on Wednesday, December 27th. Wedbush boosted their price target on Vera Therapeutics from $21.00 to $34.00 and gave the stock a “neutral” rating in a report on Thursday, March 21st. Guggenheim restated a “buy” rating and issued a $56.00 price target on shares of Vera Therapeutics in a research note on Friday, April 5th. Finally, Cantor Fitzgerald began coverage on shares of Vera Therapeutics in a research report on Monday, January 8th. They set an “overweight” rating on the stock.

Vera Therapeutics Price Performance

NASDAQ VERA opened at $39.52 on Friday. The company has a current ratio of 7.71, a quick ratio of 7.71 and a debt-to-equity ratio of 0.49. Vera Therapeutics has a 12 month low of $6.07 and a 12 month high of $50.78. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -17.26 and a beta of 1.05. The company’s 50 day moving average is $43.47 and its two-hundred day moving average is $26.48.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.05). As a group, research analysts anticipate that Vera Therapeutics will post -2.18 earnings per share for the current year.

Insider Buying and Selling at Vera Therapeutics

In other news, SVP Joseph R. Young sold 5,714 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total transaction of $228,560.00. Following the sale, the senior vice president now directly owns 53,171 shares of the company’s stock, valued at approximately $2,126,840. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Sean Grant sold 99,828 shares of the stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $39.61, for a total value of $3,954,187.08. Following the completion of the transaction, the chief financial officer now owns 66,337 shares of the company’s stock, valued at approximately $2,627,608.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Joseph R. Young sold 5,714 shares of Vera Therapeutics stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total value of $228,560.00. Following the completion of the transaction, the senior vice president now owns 53,171 shares of the company’s stock, valued at approximately $2,126,840. The disclosure for this sale can be found here. Insiders sold 526,551 shares of company stock worth $21,533,345 in the last quarter. 21.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VERA. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Vera Therapeutics in the 3rd quarter worth approximately $79,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Vera Therapeutics by 27.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,579 shares of the company’s stock worth $282,000 after buying an additional 4,387 shares during the period. Barclays PLC increased its position in Vera Therapeutics by 964.6% during the third quarter. Barclays PLC now owns 71,703 shares of the company’s stock valued at $983,000 after acquiring an additional 64,968 shares during the last quarter. Amalgamated Bank raised its stake in shares of Vera Therapeutics by 26.0% in the third quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock valued at $57,000 after acquiring an additional 864 shares during the period. Finally, Swiss National Bank purchased a new stake in shares of Vera Therapeutics in the third quarter valued at $668,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.